Differential Effects of Chronic Antidepressant Treatment on Swim Stress- and Fluoxetine-Induced Secretion of Corticosterone and Progesterone

GARY E. DUNCAN, DARIN J. KNAPP, STANLEY W. CARSON and GEORGE R. BREESE

UNC Neuroscience Center, Center for Alcohol Studies, Departments of Psychiatry, Anesthesiology and Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Accepted for publication January 29, 1998

Abstract

Hypersecretion of cortisol occurs in numerous patients with major depression and normalizes with clinical recovery during the course of chronic antidepressant treatment. These clinical data suggest that investigation of the effects of antidepressant treatments on the regulation of the brain-pituitary-adrenal axis may assist in elucidating the therapeutic basis of antidepressant actions. In the present investigation, both swim stress and acute fluoxetine challenge increased release of corticosterone and progesterone to reflect an activation of the brain pituitary-adrenal axis. The effects of chronic antidepressant treatment (21 days) on corticosterone and progesterone secretion induced by these challenges were investigated. Chronic fluoxetine treatment (5 mg/kg/day) completely blocked the increased secretion of corticosterone and progesterone in response to the acute fluoxetine challenge. Chronic treatment with desipramine, imipramine or amitriptyline (15 mg/kg/day) also markedly attenuated fluoxetine-induced corticosterone and progesterone secretion. However, chronic treatment with the monoamine oxidase inhibitors, phenelzine (5 mg/kg) and tranylcypromine (5 mg/kg), did not affect this hormonal response to acute fluoxetine challenge. Plasma levels of fluoxetine after acute challenge were not significantly different for the various chronic antidepressant treatment conditions from the chronic saline controls; therefore, an increase in the metabolism of fluoxetine can not explain the antagonism of the fluoxetine-induced hormonal response after chronic antidepressant treatment. In contrast to the effects of selected antidepressants on acute fluoxetine-induced steroid release, chronic treatment with imipramine (20 mg/kg/day), fluoxetine (5 mg/kg/day) or phenelzine (5 mg/kg) did not significantly alter this swim stress-induced corticosterone or progesterone secretion. Because chronic fluoxetine and tricyclic antidepressant drugs blocked the acute action of fluoxetine to increase adrenal cortical secretion, but did not alter swim stress-induced secretion of these steroids, we propose that distinct neurochemical mechanisms control fluoxetine and swim stress-induced steroid release. We speculate that the substantial adaptive response to those chronic antidepressant treatments, which minimize the effect of acute fluoxetine challenge to increase in corticosterone and progesterone secretion, may be relevant to the therapeutic actions of these drugs.

Several measures of brain-pituitary-adrenal axis function are elevated in major depressive illness (Ettigi and Brown, 1977; Holsboer and Barden, 1996). For example, a substantial portion of depressed patients have chronically elevated cortisol (Gibbons, 1964; Sachar, 1975) and also exhibit a subsensitive negative feedback system, as reflected by attenuated inhibition of cortisol secretion in response to dexamethasone (Stokes et al., 1975; Carroll et al., 1981). Additionally, in depressed patients, cerebral spinal fluid levels of CRF are elevated (Banki et al., 1987; Nemeroff et al., 1984) and CRF mRNA in the paraventricular nucleus of depressed suicide victims is markedly higher than in control subjects (Raadsheer et al., 1995). Depressed patients also exhibit a supersensitive adrenocorticotropin response to systemically administered CRF (Holsboer et al., 1987; Schmider et al., 1995). Because stress results in activation of the hypothalamic-pituitary-adrenal axis (Ganong and Forsham, 1960), the well-documented disturbances in the control of corticoid function in depression suggest that depressed patients may be in a state of chronic stress (Rubin et al., 1987). In the course of chronic antidepressant drug treatment, normalization of adrenal cortical secretion precedes or coincides with clinical recovery from depression (Linkowski et al., 1987; Steiger et al., 1989; Souetre et al., 1989).

In addition to stress, the brain-pituitary-adrenal axis is induced by acute treatment with serotonin uptake inhibitors and other drugs that increase the synaptic availability of serotonin, such as 5-hydroxytryptophan (Fuller and Snoddy, 1990). The magnitude of increased corticosterone secretion in
Chronic antidepressant treatment and hormonal responses to acute fluoxetine challenge. Rats were injected daily for 3 weeks with imipramine-HCl (15 mg/kg), fluoxetine (5 mg/kg), desipramine-HCl (15 mg/kg), amitriptyline (15 mg/kg), phenelzine (5 mg/kg) or tranylcypromine (7 mg/kg) before the hormonal response to a challenge dose of fluoxetine was assessed. The 5 mg/kg challenge dose of fluoxetine was chosen because preliminary studies demonstrated that this dose induced robust secretion of corticosterone and progesterone. Furthermore, previous work by Fuller and Snoddy (1990) had shown that this dose was slightly submaximal. Trunk blood was collected and stored on ice until centrifugation to allow collection of the serum. Previous work showed that peak levels of corticosterone are obtained 40 min after i.p. injection of fluoxetine and that the levels of the hormone remain high and constant from 40 to 60 min after injection (Fuller and Snoddy, 1990). Therefore, for the acute fluoxetine challenge, rats were injected with fluoxetine-HCl (5 mg/kg), 20 to 24 hr after the final saline or drug injection in the 3-week drug treatment series, and sacrificed 40 min later.

Chronic antidepressant treatment and hormonal measurement in the forced swim test. Rats were injected daily i.p for 3 weeks with 0.9% saline, imipramine-HCl (20 mg/kg) or fluoxetine-HCl (5 mg/kg). The dose of 20 mg/kg imipramine considered the maximal dose for the drug for chronic administration and in previous work was demonstrated to antagonize swim stress-induced Fos (Duncan et al., 1996). Desipramine was not examined in this work with the swim test because imipramine is metabolized to desipramine and substantial levels of this demethylated metabolite are present in brain after administration of imipramine. After the chronic saline or antidepressant treatment, rats were processed in the forced swim test (Porsolt et al., 1978). For the conditioning swim on the first day of the test, the rats were placed in the swim tanks (40×19 cm Plexiglas cylinders) containing water (25°C) at a depth of 16 to 17 cm for 15 min. The final drug or saline injection was given after the conditioning swim. On the next day, for the test swim, the rats were placed in the tanks (25°C water) for 5 min and the duration of immobility measured. Rats were sacrificed 30, 60 or 120 min after the test swim, and trunk blood was collected and stored on ice until centrifugation.

Measurement of serum corticosterone and progesterone. Serum levels of corticosterone and progesterone were measured with radioimmunoassay kits (ICN Biomedicals, Inc., Costa Mesa, CA) according to the manufacturer’s instruction, with 125I-corticosterone and 125I-progesterone. Duplicate samples for each rat were assayed for each hormone. The approximate detection limits for the corticosterone and progesterone were 10 and 0.1 ng/ml, respectively. There was less than 1% cross-reactivity between corticosterone and progesterone for the respective antisera in the kits.

Measurement of serum fluoxetine. Serum fluoxetine and norfluoxetine metabolite were determined by a high-performance liquid chromatographic method. Fluoxetine and norfluoxetine were extracted from 100-μl serum samples with hexane/n-butylamine (9:1) after the addition of internal standard (imipramine) and pH adjustment with ammonium hydroxide. The organic phase was evaporated to dryness under a gentle stream of nitrogen at room temperature. After reconstitution with 75 μl of methanol, the sample was transferred to injection vials. Fluoxetine, norfluoxetine and internal standard were separated on a 3-μm (4.6×250 mm) Hypersil silica RP column (Keystone Scientific, Inc, Bellefonte, PA) and a mobile phase of acetonitrile/methanol/ammonium hydroxide (860:140:5) at 2.0 ml/min. Quantitation of each compound was performed with UV detection at 254 nm (Linear Instruments, Reno, NV) and Chrom Perfect chromatographic software (version 2.05, from Justice Innovations, Inc., Mountainview, CA). Standard curves were linear from 25 ng/ml, the lower limit of quantitation, up to 1000 ng/ml for both compounds. The within- and between-day coefficients of variation were <9%.

Statistics. Data were analyzed by two-way analysis of variance and post hoc comparisons were made with Tukey’s test.
Results

Effects of acute fluoxetine challenge on secretion of corticosterone and progesterone. In accord with previous results (Stark et al., 1985; Fuller and Snoddy 1990), administration of fluoxetine (5 mg/kg) induced a robust secretion of corticosterone (fig. 1) that was similar in magnitude to that induced by swim (compare with figs. 8–10). Additionally, just as with stress in male rats (Purdy et al., 1991), acute fluoxetine administration resulted in an increase in progesterone (fig. 1). To determine whether the increased secretion of these steroids involved activation of the brain-pituitary-adrenal axis, the synthetic glucocorticoid dexamethasone was administered 4 hr before fluoxetine injection. Dexamethasone is a potent synthetic glucocorticoid that suppresses adrenal cortical secretion by activating negative feedback mechanisms in the brain and pituitary gland (Meikle and Tyler, 1977). Pretreatment of rats with dexamethasone completely blocked fluoxetine-induced increases in corticosterone and progesterone secretion (fig. 1). These data indicate that fluoxetine induces the secretion of these steroids via an action on the brain and/or the pituitary gland.

Effects of chronic and subchronic treatment with fluoxetine on corticosterone and progesterone secretion in response to acute fluoxetine challenge. To evaluate the effect of chronic fluoxetine on the fluoxetine-induced increase in steroids, rats were challenged with 5 mg/kg fluoxetine after chronic administration of 0.9% saline or fluoxetine (5 mg/kg/day for 21 days). The fluoxetine challenge dose was given 20 to 24 hr after the final injection in the chronic fluoxetine treatment series. Chronic treatment with fluoxetine completely blocked the effects of the acute fluoxetine challenge on both corticosterone and progesterone secretion (fig. 2). In contrast to the effects of chronic fluoxetine treatment, rats injected with fluoxetine for 1 day, and challenged with 5 mg/kg fluoxetine the next day, did not exhibit diminished hormonal responses to the fluoxetine challenge (fig. 3).

Effects of chronic treatment with other antidepressant drugs on acute fluoxetine-induced corticosterone and progesterone secretion. To determine whether chronic treatment with antidepressants having pharmacological properties different from fluoxetine would antagonize the corticosterone and progesterone response to acute fluox-

Fig. 1. Acute fluoxetine-induced increase in corticosterone and progesterone secretion: Effect of dexamethasone. Rats were pretreated with saline (SAL) or dexamethasone (DEX, 0.5 mg/kg) 4 hr before challenge with saline or fluoxetine (FLU). Rats were sacrificed 40 min after the saline or fluoxetine challenge. Data are means ± S.E.M. with n = 6 for each group. *P < .01 compared with SAL; **P < .01 compared with SAL-FLU.

Fig. 2. Effect of chronic fluoxetine treatment on corticosterone and progesterone secretion in response to acute fluoxetine challenge. Rats were injected daily for 21 days with 0.9% saline or fluoxetine (5 mg/kg). Twenty-four hours after the final injection, a challenge dose of fluoxetine (5 mg/kg) or saline was administered and rats were sacrificed by decapitation 40 min later. Abbreviations: SAL, saline; FLU, fluoxetine. The number of rats in each group are given above the bars. Data are presented as the mean ± S.E.M. for each group. *P < .01 compared with SAL-SAL; **P < .01 compared with SAL-FLU.
etamine challenge, rats were treated chronically with various other clinically used antidepressants before an acute fluoxetine challenge. Antidepressants chosen for study were imipramine, desipramine, amitriptyline, tranylcypromine and phenelzine. Imipramine and amitriptyline inhibit the uptake of both serotonin and norepinephrine (Wood et al., 1986), whereas desipramine has predominant actions on norepinephrine uptake with little effect on serotonin uptake (Randrup and Braestrup, 1977). Desipramine also was chosen for study to determine whether an antidepressant drug, which does not directly affect serotonin function, would induce an adaptive response in serotonergic control of the brain-pituitary-adrenal axis, as assessed by the acute fluoxetine challenge. Chronic administration of imipramine, desipramine (fig. 4) or amitriptyline (fig. 5) markedly attenuated corticosterone and progesterone secretion induced by acute fluoxetine challenge. In contrast to the blockade by the tricyclic antidepressants on fluoxetine-induced steroid secretion, chronic treatment with the MAO inhibitors, tranylcypromine and phenelzine, did not affect the hormonal response to acute fluoxetine challenge (fig. 5).

Effect of chronic antidepressant treatments on serum levels of fluoxetine. Because the reduced corticosterone and progesterone responses to acute fluoxetine challenge could have been caused by an altered metabolism of fluoxetine during the course of the chronic treatment of the antidepressants, plasma levels of fluoxetine were measured after chronic antidepressant treatments that antagonized the steroid response to fluoxetine. Serum fluoxetine levels after acute challenge were not significantly different in rats treated chronically with saline, fluoxetine, imipramine or desipramine (fig. 6). Serum norfluoxetine levels were significantly lower in rats treated chronically with desipramine and imipramine, but not fluoxetine (fig. 6). However, because fluoxetine levels were not reduced in the rats treated chronically with imipramine or desipramine, altered fluoxetine metabolism cannot explain the attenuated hormonal responses to acute fluoxetine observed after chronic administration of these tricyclic antidepressants.

Fig. 3. Lack of effect of 1-day fluoxetine treatment on corticosterone and progesterone secretion in response to fluoxetine challenge. Rats were treated with fluoxetine (FLU, 5 mg/kg) or saline (SAL) on day 1 and challenged with saline or fluoxetine (5 mg/kg) on day 2, as indicated. SAL-FLU levels of corticosterone and progesterone after SAL-FLU were not significantly different from levels in the FLU-FLU-treated rats.

Fig. 4. Effect of chronic imipramine and desipramine treatment on fluoxetine-induced secretion of corticosterone and progesterone. Rats were injected daily for 21 days with 0.9% saline, imipramine or desipramine (15 mg/kg for each). Twenty-four hours after the final injection of desipramine and imipramine, a challenge dose of fluoxetine (5 mg/kg) was given and rats were sacrificed by decapitation 40 min later. The number of rats in each group are given above the bars. Data are presented as the mean ± S.E.M. for each group. Abbreviations: SAL, saline; IMI, imipramine; DMI, desipramine. *P < .01 compared with SAL-SAL; **P < .01 compared with SAL-FLU.
Effects of chronic treatment with fluoxetine, imipramine and phenelzine on swim stress-induced immobility and corticosterone and progesterone secretion. To determine whether the marked reduction in fluoxetine-induced corticosterone and progesterone secretion after chronic antidepressant treatment was caused by generalized desensitization of the brain-pituitary-adrenal axis, the effects of chronic treatment with imipramine and fluoxetine on swim stress-induced secretion of these hormones was examined. No significant difference in basal or swim-induced corticosterone or progesterone levels was observed between rats treated chronically (3 weeks) with imipramine (fig. 7), fluoxetine (fig. 8) or phenelzine (fig. 9) and those treated with saline.

Even though no effect of chronic antidepressant treatment was found on swim-induced steroid secretion, all three antidepressant drugs reduce the duration of immobility in the swim test (fig. 10; Porsolt et al., 1978). As reported previously (Detke et al., 1995), behavioral responses to fluoxetine were qualitatively distinct from the behavioral response obtained with imipramine and phenelzine. After treatment with imipramine and phenelzine, rats jumped from the bottom of the swim tanks and attempted to vigorously climb the walls of the tanks for much of the nonimmobile time. In contrast, such behavior was not exhibited by the fluoxetine-treated rats, which exhibited less vigorous “escape-directed” behavior, but instead would swim around the tank without jumping or climbing during the nonimmobile time. Thus, although a behavioral consequence could be elicited by the chronic administration of these antidepressants, their chronic treatment failed to affect the secretion of corticosterone or progesterone in response to swim stress.

Discussion

The present studies demonstrated that acute administration of fluoxetine, as well as swim stress, induced a robust increase in corticosterone and progesterone secretion. Because depressed patients can have chronically elevated cortisol levels (Gibbons, 1964; Sachar, 1975), it seems paradoxical that an acute response to an antidepressant (i.e., induction of corticosterone secretion by fluoxetine) is similar to a symptom manifested in some depressed patients. However, the recognized requirement for chronic antidepressant administration to achieve a therapeutic response in depressed patients, which includes a reduction in their hypercortisolism, demonstrates that acute pharmacological
properties of fluoxetine do not account for the clinical efficacy of this drug class. One hypothesis tested in the present work was that chronic treatment with antidepressants would induce adaptive changes leading to an attenuation of the acute fluoxetine and stress-induced adrenal cortical activation. Our goal was to characterize a model system that could be used to explore antidepressant-induced neurochemical adaptation relevant to neural mechanism(s) by which antidepressants reduce the hypersecretion of cortisol in depressive illness.

Acute effects of fluoxetine and swim stress on corticosterone and progesterone secretion. Other investigators previously have observed that swim stress can increase progesterone as well as corticosterone and stress-induced adrenal cortical activation. Our goal was to characterize a model system that could be used to explore antidepressant-induced neurochemical adaptation relevant to neural mechanism(s) by which antidepressants reduce the hypersecretion of cortisol in depressive illness.

Fig. 7. Lack of effect of chronic imipramine treatment on swim-induced corticosterone or progesterone. Rats were injected daily with imipramine (20 mg/kg) for 21 days before processing in the forced swim test as described under “Materials and Methods.” After the test swim (20–24 hr after the final drug or saline injection), the rats were transferred to their home cages and sacrificed by decapitation at the indicated times after the swim for collection of trunk blood. Rats that received chronic injections of saline or imipramine and were not swum were sacrificed 20 to 24 hr after the final injection. The number of rats for each time and treatment are indicated above the bars. Data are expressed as the mean ± S.E.M. for each group.

Fig. 8. Lack of effect of chronic fluoxetine treatment on swim-induced corticosterone or progesterone. Rats were injected daily with fluoxetine (5 mg/kg) for 21 days before processing in the forced swim test as described under “Materials and Methods.” After the test swim (20–24 hr after the final drug or saline injection), the rats were transferred to their home cages and sacrificed by decapitation at the indicated times after the swim for collection of trunk blood. Rats that received chronic injections of saline or fluoxetine and were not swum were sacrificed 20 to 24 hr after the final injection. The number of rats for each time and treatment are indicated above the bars. Data are expressed as the mean ± S.E.M. for each group.

Possibility of acute fluoxetine-induced corticosterone and progesterone secretion. Inhibition of the serotonin transporter by fluoxetine results in an increased extracellular fluid level of serotonin (Fuller and Snoddy, 1990). Therefore, the most probable mechanism by which acute fluoxetine induces activation of the brain-pituitary-adrenal axis would be by increasing the synaptic concentration of serotonin, with consequent increased activation of a serotonin receptors. Nonetheless, the specific serotonergic receptor mechanism involved in the neuroendocrine activation by fluoxetine is unknown. Both 5HT-2 and 5HT-1A receptor agonists have been shown to increase corticosterone
levels (Urban et al., 1986; Fuller et al., 1986; Koenig et al., 1987; Fuller and Snoddy, 1990) and chronic fluoxetine treatment reduces corticosterone secretion induced by the 5HT-1A agonists (Li et al., 1993, 1994). However, 5-HT-1A and 5HT-2 receptor antagonists do not attenuate the acute fluoxetine-induced increase in corticosterone levels (Fuller and Snoddy, 1990). Furthermore, interactions between the two receptor subtypes cannot explain the effects of fluoxetine on corticosterone secretion, because coadministration of 5HT-1A and 5HT-2 receptor antagonists also did not block this fluoxetine-induced endocrine response (Fuller and Snoddy, 1990). Consequently, if enhancement of synaptic availability of endogenous serotonin by the fluoxetine is responsible for the adrenal cortical activation, a serotonin receptor subtype other than 5HT-1A or 5HT-2 may be involved. Although one potential candidate is the recently cloned 5HT-7 receptor, which is enriched in the hypothalamus (To et al., 1995; Sleight et al., 1995), no direct information currently documents specific 5HT receptor subtypes in the control of fluoxetine-induced steroid release.

Effect of chronic antidepressant administration on fluoxetine-induced steroid secretion. Chronic administration of all antidepressant drug types which inhibit uptake of serotonin, including fluoxetine (Stark et al., 1985), imipramine and amitriptyline (Randrup and Braestrup, 1977; Wood et al., 1986), blocked the increase in corticosterone and progesterone induced by the acute fluoxetine challenge, without affecting base-line levels of these steroids. Likewise, chronic administration of desipramine, which potently inhibits norepinephrine uptake with minimal effect on serotonin uptake (Randrup and Braestrup, 1977), also antagonized fluoxetine-induced steroid secretion. These findings suggest that chronic inhibition of either serotonin uptake or noradrenergic uptake results in adaptive changes that markedly attenuate the ability of fluoxetine to induce secretion of corticosterone and progesterone. Unlike the effects of chronic treatment with fluoxetine and tricyclic antidepressant drugs, chronic treatment with the MAO inhibitors, phenelzine and tranylcypromine, did not result in a significant attenuation of the corticosterone and progesterone responses to the acute challenge with fluoxetine. Thus, the attenuation of fluoxetine-induced steroid secretion is not a general feature of all antidepressant drugs.

Possible adaptive mechanisms responsible for the antagonism of the steroid release by chronic antidepressant treatments. After chronic fluoxetine treatment, in vivo microdialysis studies have shown that extracellular fluid levels of serotonin are markedly elevated after the last chronic fluoxetine treatment (Rutter et al., 1994). The increased extracellular level of serotonin induced by fluoxetine after chronic treatment was even greater than after an acute fluoxetine challenge (Rutter et al., 1994). Thus, a reduced effectiveness of fluoxetine to release serotonin after chronic administration does not appear to be responsible for the observed blockade of the steroid release after acute fluoxetine administration. Additionally, serum levels of fluoxetine after acute challenge were similar in groups treated chronically with saline or with the antidepressants that blocked the acute steroid response to fluoxetine challenge. Therefore, an increased metabolism of fluoxetine can not explain the antagonism of fluoxetine-induced steroid release by chronic treatment of selected antidepressant drugs.

Chronic treatment with antidepressant drugs which block serotonin or norepinephrine uptake sites must result in a substantial neurochemical adaptation in neural circuits which regulate fluoxetine-induced adrenal hormone secretion, as both types of drugs antagonized this response. Although chronic treatment with fluoxetine has been shown to
reduce corticosterone secretion induced by 5HT-1A agonists, (Li et al., 1993), chronic treatment with desipramine, which also reduces the acute fluoxetine-induced increases in steroid secretion, does not modify 5HT-1A agonist-induced corticosterone secretion (Li et al., 1994). These data, considered with the data of Fuller and Snody (1990) discussed above, suggest that the antagonism of fluoxetine-induced adrenal hormone secretion after chronic antidepressant treatment can not be explained by a reduction in the sensitivity of 5HT-1A receptors.

Chronic desipramine treatment, which antagonizes fluoxetine-induced release of steroids, causes down-regulation of beta adrenergic receptor number and function (see Baker and Greenshaw, 1989). Although chronic fluoxetine treatment also antagonizes steroid release by acute fluoxetine administration, chronic fluoxetine does not cause a down-regulation of beta adrenergic receptors (Johnston, 1991). As observed for the tricyclic antidepressant drugs (Baker and Greenshaw, 1989), chronic administration of MAO inhibitors also induces an adaptive down-regulation of beta adrenergic receptors; however, this class of antidepressants does not have an effect on the acute fluoxetine-induced secretion of steroids. Collectively, these latter data suggest that antidepressant-induced adaptive changes in noradrenergic receptor function cannot explain the present finding that selected antidepressant drugs block acute fluoxetine-induced release of steroids.

Chronic administration of fluoxetine, tricyclic antidepressants and MAO inhibitors has been shown to reduce the expression of mRNA for CRF in the paraventricular nucleus of the hypothalamus (Brady et al., 1991, 1992). However, this action is apparently not sufficient to explain the present results, because MAO inhibitors are ineffective in reducing fluoxetine-induced hormonal secretion. Chronic fluoxetine administration also has been shown to down-regulate the 5-HT-7 receptor subtype in hypothalamic membrane preparations after chronic fluoxetine treatment (Sleight et al., 1995); however, it is not known whether chronic desipramine affects this 5-HT receptor subtype. Thus, it can be concluded that the adaptive mechanism(s) by which chronic antidepressant treatment blocks the acute action of fluoxetine to stimulate corticosterone and progesterone secretion has yet to be identified.

**Chronic antidepressant treatments on forced swim-induced immobility and corticosterone and progesterone secretion.** The final aspect of our investigation was to determine whether chronic antidepressant treatment would antagonize the release of corticosterone and progesterone induced by swim stress (Purdy et al., 1991). This particular stressor was chosen because the protocol of forced swim is used to screen for antidepressant action (Porsolt et al., 1978). As expected from previous work (Duncan et al., 1985, 1996), chronic administration of the antidepressant drugs fluoxetine, imipramine and phencelzine resulted in a significant reduction in the immobility in the forced swim test paradigm. Even though chronic administration of the antidepressants produced a behavioral change induced by forced swim, swim stress-induced secretion of these steroids was not affected by such chronic antidepressant exposure. The inability of chronic treatment with fluoxetine and imipramine to modify adrenal cortical secretion in response to swim stress suggests that a generalized down-regulation of the brain-pituitary-adrenal axis was not induced by the antidepressant drug treatments.

In contrast to the present data showing no effect of chronic antidepressant treatment on swim-induced activation of the brain-pituitary-adrenal axis, Reul et al. (1993) found that chronic administration of amitriptyline reduced the corticosterone response induced by placing rats in a novel environment. Differences in the nature of these stressors and the possible activation of differing neural pathways by the stressors could explain the ability of chronic treatment to block the stress response induced by the novel environment but not affect the increase in corticosterone induced by the swim. On the other hand, the magnitude of the stress response could be a consideration, because swim stress could be expected to be more stressful than novelty stress. In this regard, swim stress typically increased corticosterone levels to 300 to 400 ng/ml, whereas in the study of Reul et al. (1993), the novelty stress condition increased corticosterone to about 250 ng/ml. Thus, one interpretation could be that chronic antidepressant treatment could not overcome the hormonal response of the more severe swim stress compared with the stress of novel environment. However, contrary to this interpretation, acute fluoxetine treatment increased steroids to a level as great as that observed with swim stress, yet this increase by the acute fluoxetine challenge was blocked completely by the chronic antidepressant treatments.

Therefore, the differential effects observed for the antidepressant treatments on swim stress-induced and fluoxetine-induced alterations in corticosterone and progesterone secretion may involve differing neural mechanisms associated with regulation of adrenal steroid secretion. In this regard, at least two distinct pathways controlling CRF release have been proposed previously, one originating from brainstem structures and the other involving projections from limbic regions of the forebrain (Herman and Cullinan, 1997; Sawchenko, 1990). Whether altered activity in these distinct pathways contributes to the differential effects of chronic antidepressant treatment on fluoxetine- and stress-induced adrenal steroid secretion deserves investigation.

**Acknowledgments**

The authors appreciate the supply of fluoxetine from Margaret Niedenthal at Lilly Laboratories, assistance in typing the manuscript by Doris Lee and the excellent technical assistance of Edna Titus.

**References**


Antidepressant Effects on Corticoid Secretion


Send reprint requests to: George R. Breese, Ph.D., Center for Alcohol Studies, CB# 7178, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.

Downloaded from Jpet.aspetjournals.org at ASPET Journals on October 25, 2017